Sofregen Medical has acquired SERI surgical scaffold product line from Allergen for an undisclosed amount.
The financing for the deal as been provided by Sofregen’s founding investors including Polaris Partners and others.
The purchase is in line with Sofregen’s vision of advancing several silk-based solutions for the treatment of patients with soft-tissue defects.
SERI is being considered as the only silk-based surgical mesh that is currently used for soft tissue support in plastic and reconstructive surgical procedures.
Sofregen Medical chairman Howard Weisman said: “Silk has proven to promote regeneration of the body’s own tissue, allowing for tremendous potential to effectively repair both disfiguring injuries and delicate defects.
“The global market for products to address soft-tissue aesthetics is estimated to reach $5 billion next year.
“We are excited to be adding the SERI product line to our platform, and look forward to continuing to help surgeons who are eager to restore confidence and improve the quality of life for patients around the world.”
Via bio replacement, SERI supports neovascularization and native tissue generation over time. It has been used in more than 10,000 surgical procedures that need surgical mesh.
Sofregen also has a pipeline of novel, injectable, silk-based products currently under development.
Sofregen’s incoming president and COO Chris White said: “As the new supplier of SERI Surgical Scaffold, Sofregen is committed to meeting the needs of customers without disruption.
“We are bolstering our commercial organization, adding field-based sales representatives and medical affairs personnel to support the SERI product line with outstanding service.”